Plaque Psoriasis

These data resulted from comparisons of the time to onset of action among various available systemic medications for those with plaque psoriasis.

This online diagnostic tool’s implementation among study participants led to increased confidence in making diagnoses of chronic plaque psoriasis.

In this Month in Review, we highlighted some of the most notable stories covered in the dermatology space during September 2024.

A study shows secukinumab clears skin lesions faster than ustekinumab in generalized pustular psoriasis, with improved responses observed by week 2.

Study findings highlight the individual and combined impact of smoking tobacco and drinking alcohol on achieving PASI75 after 8 weeks of treatment.

A small percentage of participants with psoriasis reported adequate adherence, with nearly half showing low adherence to phototherapy treatment.

These 28-week data on twice-daily ESK-001 highlight the drug’s safety and efficacy among patients with psoriasis.

These data were presented at EADV 2024 by UCB, with presenters highlighting positive long-term efficacy findings for bimekizumab among patients with plaque psoriasis.

These data suggest that the use of narrowband UVB phototherapy at home among patients with guttate or plaque psoriasis may function as a slightly less costly alternative to in-office use.

These data from the DISCREET study highlight the impact of apremilast on men and women with genital psoriasis.

The FDA has set a PDUFA target action date of May 22, 2025, for roflumilast foam 0.3% for individuals aged ≥12 with scalp and body psoriasis.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

At Maui Derm NP+PA Fall 2024, bimekizumab data demonstrates a consistent safety profile in moderate to severe plaque psoriasis over 4 years, with decreasing event rates over time.

These real-world data resulted from an interim analysis of the PSoSA study on psoriasis patients with scalp itch, nail pain, and quality of life impairment.

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

Commercial and government-based sources on Google scored the highest in quality, while medical practices scored the lowest, for information on psoriasis.

In this analysis, the differences in adverse events resulting from JAKi among adults and children were evaluated.

These findings further endorse the need for health care quality improvements for veterans, given the rates of melanoma, skin cancer, and psoriasis.

In this review of August 2024, the editorial team highlighted major stories from the previous month related to FDA approvals and medications for atopic dermatitis and psoriasis.

These data suggest that there are a subset of individuals with complete skin clearance of their psoriasis who report residual effects of their condition.

Prefilled pens and fewer injections improve satisfaction in psoriasis patients with needle phobia, enhancing adherence and treatment effectiveness, a study finds.

Patients with psoriasis show greater H. pylori infection rates, but no link to psoriasis severity, suggesting further research is needed on this potential connection.

The Harris Poll evaluated patient preferences for psoriasis therapy, highlighting patient views through an online survey.

These data highlight the necessity of equality in access to treatment and to the future development of psychological intervention measures using country-specific differences.

This new analysis highlights the effect of this selective allosteric tyrosine kinase 2 inhibitor as an oral treatment for moderate-to-severe psoriasis.

Rates of adverse events leading to discontinuation were similar between populations of moderate-to-severe psoriasis and psoriatic arthritis.

These data on the efficacy of bimekizumab suggest positive therapeutic effects on nail, scalp, and genital lesions as well as quality of life.

This analysis suggests additional support may be required for tildrakizumab-associated adverse drug reactions, given these new insights.

These data suggest that physical activity interventions can lead to visible improvements in PASI scores after 20 weeks of implementation, as well as cardiometabolic improvements.

In this analysis, the biggest predictors of biologic initiation among individuals with diagnoses of psoriasis were evaluated.